Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Pfizer and Janssen form molecule-sharing pact
by Ryan Cross
October 27, 2018
| A version of this story appeared in
Volume 96, Issue 43
The drug giants Pfizer and Janssen have formed a partnership in which they will share some of their unique molecules with each other for drug design. The collaboration is part of the Building Block Exchange (BBXC), which the duo has launched to facilitate one-for-one compound swaps. They hope more companies will join BBXC. Similarly, last year, Boehringer Ingelheim announced it would share molecules through its opnMe.com platform. In 2015, AstraZeneca and Sanofi agreed to exchange 210,000 compounds from their libraries.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X